Your browser doesn't support javascript.
loading
A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors.
Cunningham, Christopher; Jabri, Ahmad; Alhuneafat, Laith; Aneja, Ashish.
Afiliação
  • Cunningham C; Department of Medicine, The MetroHealth System, Cleveland, OH.
  • Jabri A; Department of Cardiovascular Disease, Henry Ford, Detroit, Michigan, USA. Electronic address: jabri.ahmad91@gmail.com.
  • Alhuneafat L; Department of Medicine, Allegheny Health Network, Pittsburgh, PA.
  • Aneja A; Heart and Vascular Division, The MetroHealth System, Cleveland, OH.
Curr Probl Cardiol ; 48(10): 101817, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37211299
ABSTRACT
Sodium-glucose cotransport 2 inhibitors (SGLT2i) are a class of drugs initially approved by the Food and Drug Association (FDA) as antihyperglycemic agents for patients with type 2 diabetes mellitus (DM). However, lately, these agents (Canagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin, and Dapagliflozin) have become better known for their cardiovascular (CV) and reno-protective effects. In this comprehensive review and analysis, we display the advancement of Sodium Glucose Cotransport Inhibitors have shown in cardiology, specifically heart failure in a concise, yet thorough manner.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article